PARP1 and cancer: PolyADP ribose polymerase (PARP) inhibitors (PARPi) were found to be synthetic lethal in cancers with aberrations in HR mediated by BRCA6 and multiple PARPi have now been approved for the treatment of several cancer subtypes, including gBRCA+ breast cancers7.